Amid Merck publicity blast, NEJM questions Gardasil vaccine

[Guest guest]

Excerpted from the Wall Street Journal

Medical Journal Questions Efficacy of HPV Vaccine

By Carreyrou and Winstein

Word Count: 558 | Companies Featured in This Article: Merck

An editorial published in the New England Journal of Medicine raises

questions about the overall effectiveness of Merck & Co.'s cervical-

cancer vaccine, Gardasil, and advises policymakers, doctors and

parents to adopt " a cautious approach " toward vaccination.

The editorial accompanied a study published in the medical journal

analyzing results of a clinical trial of the vaccine, which targets

two types of the human papillomavirus thought to cause most cervical

cancers and two other types that cause genital warts.

Meryl Nass, MD

Mount Desert Island Hospital

Bar Harbor, Maine 04609

207 288-5081 ext. 220